Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies.

Autor:	Fernandez Sanahuja L; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain., Miralpeix E; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain.; School of Medicine, Universitat Pompeu Fabra, 08003 Barcelona, Spain., Solé Sedeño JM; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain.; School of Medicine, Universitat Pompeu Fabra, 08003 Barcelona, Spain., Baucells M; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain., Fabregó B; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain., Sierra A; Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain., Mancebo G; Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain.; School of Medicine, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	International journal of environmental research and public health [Int J Environ Res Public Health] 2024 Aug 14; Vol. 21 (8). Date of Electronic Publication: 2024 Aug 14.
DOI:	10.3390/ijerph21081063
Abstrakt:	Background: This study aimed to evaluate the incidence of lymphadenopathies after COVID-19 vaccination and their impact on the clinical management of gynecologic oncology patients. Methods: A retrospective observational study was conducted involving patients who underwent abdominopelvic or thoracoabdominopelvic CT scans during diagnosis or follow-up. Patients were classified into a vaccinated group (Vac group) and a non-vaccinated group (NoVac group). The radiological appearance of lymphadenopathies was categorized as low or high risk of malignancy, and management strategies were recorded as standard management or additional assessment. Results: 75 patients were included, with 44 in the Vac group and 31 in the NoVac group. The incidence of lymphadenopathies was similar between the groups: 34.1% in the Vac group and 32.3% in the NoVac group ( p = 0.868). High-risk lymphadenopathies were observed in 20.4% of the Vac group and 22.6% of the NoVac group, while low-risk lymphadenopathies were seen in 13.6% of the Vac group and 9.7% of the NoVac group ( p = 0.691). Standard management was the most common approach, used in 80.0% of the Vac group and 100.0% of the NoVac group ( p = 0.25). Conclusions: COVID-19 vaccine does not increase the incidence of lymphadenopathies in imaging tests of gynecological cancer patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu